Related Experiment Video
Updated: Mar 14, 2026
10:39
Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy
Published on: April 16, 2019
8.2K
Targeting Single Molecules in Asthma Benefits Few
1School of Anatomy, Physiology, and Human Biology, University of Western Australia, Crawley, Australia.
Trends in Molecular Medicine
|October 4, 2016
Summary
Severe asthma treatment is challenging, as targeting single molecular defects yields minimal benefits due to variable patient pathogenesis. Future therapies may require broader approaches for effective asthma management.
Area of Science:
- Pulmonology
- Immunology
- Pharmacology
Background:
- Asthma is a common respiratory condition with variable severity.
- Severe, difficult-to-treat asthma affects individuals unresponsive to standard therapies.
- Emerging pharmaceuticals target specific molecular pathways in asthma.
Purpose of the Study:
- To evaluate the efficacy of targeted molecular therapies in severe asthma.
- To investigate the molecular pathogenesis of severe asthma.
- To assess the clinical trial outcomes of novel asthma drug candidates.
Main Methods:
- Clinical trials of pharmaceuticals blocking or mimicking endogenous molecules.
- Assessment of patient response to guideline therapies.
- Analysis of molecular defect variability in severe asthma.
Main Results:
- Few selected patients showed minimal benefit from targeted therapies.
- Significant molecular pathogenesis variability observed between severe asthma patients.
- Individual molecular defects appear to have minor contributions to disease severity.
Conclusions:
- Targeting a single molecular defect is unlikely to be effective for most severe asthma patients.
- The variable molecular basis of severe asthma necessitates personalized or combination treatment strategies.
- Current molecularly targeted therapies offer limited benefit in poorly controlled asthma.
Related Concept Videos
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
2.2K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.2K
01:19Antiasthma Drugs: Leukotriene Modifiers
2.1K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
2.1K
01:30Asthma-IV: Diagnostic and Management
3.3K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.3K
01:20Asthma: Pathogenesis and Management
1.6K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.6K
01:26Asthma-II: Pathophysiology and Classification
4.8K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.8K
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
1.9K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
1.9K